AstraZeneca to support WIN Consortium’s cancer research efforts

AstraZeneca has joined the Worldwide Innovative Network (WIN) Consortium, a move that will aid global efforts to research and develop new personalised cancer treatment methods.

The company has become the newest member of the unique global network, which brings together leading academics, industries, payors and patient advocacy organisations. The consortium's aim is to make cancer precision medicine a reality for patients worldwide.

Also joining the WIN Consortium alongside AstraZeneca are the German Cancer Research Centre and the European Organisation for the Research and Treatment of Cancer, meaning it now has 32 members spanning five continents.

WIN's goal is to significantly improve survival and quality of life of cancer patients in the next three years.

Dr Antoine Yver, head of oncology at AstraZeneca's global medicines development unit, said: "AstraZeneca has a rich heritage in oncology research and development and we can achieve a lot by joining forces with others to progress the best science and accelerate development of the next generation of medicines."

This comes after the company agreed to work alongside Horizon Discovery to research new oncology treatments earlier this month.